<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01858259</url>
  </required_header>
  <id_info>
    <org_study_id>HEALTH-F5-2012-305495-OT3</org_study_id>
    <nct_id>NCT01858259</nct_id>
  </id_info>
  <brief_title>Treatment and Prevention of Progression of Interstitial Lung Disease in Systemic Sclerosis</brief_title>
  <official_title>Prevention and Treatment of Interstitial Lung Disease in Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gabriela Riemekasten</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Paris 5 - Rene Descartes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Florence</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Campania &quot;Luigi Vanvitelli&quot;</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Basel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pecs</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Leeds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Schoen Klinik Hamburg Eilbek</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic sclerosis (SSc) is an orphan, multiorgan disease affecting the connective tissue of
      the skin and all internal organs. Interstitial lung disease is a frequent morbidity and
      mortality-driving manifestation in systemic sclerosis.

      This observational trial (OT) is part of the collaborative project &quot;DeSScipher&quot;, one out of
      five OTs to decipher the optimal management of systemic sclerosis. Aim of this observational
      try is to identify:

        -  The state of clinical practice in Europe for prevention and treatment of interstitial
           lung disease and its impact on lung function and disease progression

        -  The potential predictors and confounders for response to therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are routinely evaluated every 3 months over a 12-months period by medical history,
      physical examination, pulmonary function tests, VAS lung score and SF-36, SHAQ. Also, their
      medication and possible medication changes will be recorded.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Proportion of patients with 10% decline in FVC</measure>
    <time_frame>1 year</time_frame>
    <description>The proportion of patients with ILD progression as defined by a 10% decline in FVC within 1 year of therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time to a 15% decline in DLCO or a drop &lt;55% of predicted lung function</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mortality due to lung fibrosis</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The need for oxygen support</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Identification of confounders</measure>
    <time_frame>1 year</time_frame>
    <description>Parameters with impact on ILD progression independent of therapies, such as SSc subgroups, presence of antibodies, presence of vasculopathy, time to therapy initiation, degree of lung fibrosis defined by FVC values, age at disease onset and at treatment initiation, gender, co-morbidities and other confounders.</description>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of the incidence of drug-related adverse events</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Evaluation of the incidence of withdrawal from treatment due to drug-related adverse events</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">1372</enrollment>
  <condition>Systemic Sclerosis</condition>
  <condition>Interstitial Lung Diseases</condition>
  <arm_group>
    <arm_group_label>cyclophosphamide</arm_group_label>
    <description>Patients receiving cyclophosphamide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>azathioprine</arm_group_label>
    <description>Patients receiving azathioprine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>mycophenolate mofetil</arm_group_label>
    <description>Patients receiving mycophenolate mofetil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>methotrexate</arm_group_label>
    <description>Patients receiving methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no therapy</arm_group_label>
    <description>Patients receiving no immunosuppressive therapy</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The study population are adult and juvenile SSc patients from the EUSTAR cohort (MEDSonline
        database) and the jSScWG cohort
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis fo SSc according to the ACR/EULAR criteria for adult or the PRES/ACR/EULAR
             criteria for juvenile SSc patients

          -  SSc patients with proven ILD (by X-ray or CT scan)

          -  Treatment with standard dosages according to current practice with (i)
             cyclophosphamide, (ii) azathioprine, (iii) mycophenolate mofetil, (iv) methotrexate,
             or (v) no therapy

        Exclusion Criterion:

          -  Patients with previous exposure to silica or asbestos
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabriela Riemekasten, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité Universitätsmedizin Berlin, Charité Centrum 12 für Innere Medizin und Dermatologie, Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Denton, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Free Hospital, University College London London</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulf Müller-Ladner, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Justus-Liebig-University Gießen, Kerckhoff Clinic, Departement of Rheumatology and Clinical Immunology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gabriela Riemekasten, Prof.</last_name>
    <email>Gabriela.Riemekasten@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christopher Denton, Prof.</last_name>
    <email>c.denton@ucl.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Université Paris Descartes, Hôpital Cochin, Service de Rhumatologie A &amp; INSERM 1016</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yannick Allanore, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Justus-Liebig-University Gießen, Kerckhoff Clinic, Departement of Rheumatology and Clinical Immunology</name>
      <address>
        <city>Bad Nauheim</city>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulf Müller-Ladner, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ingo H. Tarner, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marc Frerix, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charité Universitätsmedizin Berlin, Charité Centrum 12 für Innere Medizin und Dermatologie, Medizinische Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gabriela Riemekasten, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre for Pediatric Rheumatology, Klinikum Eilbek</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ivan Foeldvari, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pecsi Tudomanyegyetem - University of Pecs</name>
      <address>
        <city>Pecs</city>
        <zip>H-7622</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Laszlo Czirjak, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florence, Denothe Centre, Division of Rheumatology AOUC, Department of Biomedicine</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marco Matucci-Cerinic, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico, Via Pansini</name>
      <address>
        <city>Napoli-Italia</city>
        <zip>5-80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gabriele Valentini, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Felix-Platter Spital, University of Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH 4012 Basel</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ulrich Walker, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Zurich, Department of Rheumatology</name>
      <address>
        <city>Zurich</city>
        <zip>8006</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Oliver Distler, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Universitiy of Leeds, Division of Rheumatic and Musculoskeletal Disease, St James's University Hospital</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francesco Del Galdo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital, University College London</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christopher Denton, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2013</study_first_submitted>
  <study_first_submitted_qc>May 16, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2013</study_first_posted>
  <last_update_submitted>August 12, 2014</last_update_submitted>
  <last_update_submitted_qc>August 12, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Gabriela Riemekasten</investigator_full_name>
    <investigator_title>Prof. Dr. med. Gabriela Riemekasten</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Lung Diseases, Interstitial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Azathioprine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

